US Ecology (NASDAQ:ECOL) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, BidAskClub reports.
Shares of ECOL stock opened at $36.20 on Friday. US Ecology has a 1-year low of $24.94 and a 1-year high of $58.36. The stock’s 50-day moving average is $34.37 and its 200 day moving average is $34.58. The company has a market cap of $1.14 billion, a P/E ratio of -3.77 and a beta of 1.20. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.38 and a quick ratio of 2.38.
US Ecology (NASDAQ:ECOL) last issued its quarterly earnings data on Thursday, November 5th. The business services provider reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.13. US Ecology had a positive return on equity of 2.55% and a negative net margin of 32.51%. The company had revenue of $238.10 million for the quarter, compared to the consensus estimate of $237.85 million. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. On average, analysts anticipate that US Ecology will post 0.43 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of ECOL. Clarkston Capital Partners LLC boosted its stake in shares of US Ecology by 106.8% in the second quarter. Clarkston Capital Partners LLC now owns 899,887 shares of the business services provider’s stock worth $30,488,000 after acquiring an additional 464,666 shares during the last quarter. BlackRock Inc. boosted its stake in shares of US Ecology by 11.1% in the third quarter. BlackRock Inc. now owns 4,561,612 shares of the business services provider’s stock worth $149,027,000 after acquiring an additional 454,887 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of US Ecology by 14.8% in the second quarter. Vanguard Group Inc. now owns 1,846,394 shares of the business services provider’s stock worth $62,556,000 after acquiring an additional 238,525 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in US Ecology by 29.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,030,460 shares of the business services provider’s stock worth $33,665,000 after buying an additional 231,531 shares during the last quarter. Finally, WCM Investment Management LLC boosted its stake in US Ecology by 121.3% during the third quarter. WCM Investment Management LLC now owns 361,855 shares of the business services provider’s stock worth $11,822,000 after buying an additional 198,312 shares during the last quarter. 80.61% of the stock is owned by institutional investors and hedge funds.
+$307 million. That’s how much Wall Street plans to invest in this new EV battery stock. Hedge funds. Pension funds. Silicon Valley billionaires. Even trillion-dollar sovereign wealth funds from the Middle East.
US Ecology Company Profile
US Ecology, Inc, through its subsidiaries, provides environmental services to commercial and government entities in the United States, Canada, Europe, the Middle East, Africa, Mexico, internationally. It operates through two segments, Environmental Services, and Field & Industrial Services. The Environmental Services segment offers specialty material management services, including transportation, recycling, treatment, and disposal of hazardous, non-hazardous, E&P, and radioactive waste at its landfill, wastewater, deep-well injection, and other treatment facilities.
Recommended Story: What causes a recession?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle
October 2, 2020, may not rank as one of those “where were you when” moments. But when news broke that the President of the United States and the First Lady tested positive for the novel coronavirus, there was certainly a sense that we were living through a historical moment (as if we already were not).
Over the following days, several biotech and pharmaceutical companies took the headlines. However, these weren’t the vaccine stocks that investors have committed to memory. These were companies that are leading the race for antiviral therapeutics.
And with a very high profile proof of concept, therapeutics may have had their moment. It’s far too early to say whether these drugs truly carry the answer. But from the outset of the pandemic, there has been a feeling that therapeutics may carry the ultimate solution to neutralizing the most severe effects of the novel coronavirus.
As you might expect, there is no shortage of companies in the therapeutic discussion. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves.
View the “7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle”.
